Table 1

Characteristics of included studies

Author	Year	Country	Follow-up	Diagnosis of PCOS	Patient selection	Jadad score	n	Intervention
Puurunen	2013	Finland	6 months	ESHRE	Randomised, double blind	6	15	Atorvastatin 20 mg/day qd
Puurunen	2013	Finland	6 months	ESHRE	Randomised, double blind	6	13	Placebo
Raja-Khan	2010	USA	6 weeks	NIH	Randomised, double blind	5	9	Atorvastatin 40 mg/day qd
Raja-Khan	2010	USA	6 weeks	NIH	Randomised, double blind	5	11	Placebo
Sathyapalan*	2009	UK	12 weeks	ESHRE	Randomised, double blind	6	19	Atorvastatin 20 mg/day qd
Sathyapalan*	2009	UK	12 weeks	ESHRE	Randomised, double blind	6	18	Placebo
Sidika	2013	USA	3 months	ESHRE	Randomised	4	18	Metformin 850 mg/day bid+simvastatin 20 mg/d qd
Sidika	2013	USA	3 months	ESHRE	Randomised	4	20	Metformin 850 mg/day bid
Celik	2012	Turkey	12 weeks	ESHRE/ASRM	Randomised	6	18	Metformin 2000 mg/day qd+rosuvastatin 10 mg/day qd
Celik	2012	Turkey	12 weeks	ESHRE/ASRM	Randomised	6	20	Metformin 2000mg/day
Kazerooni	2010	Iran	12 weeks	ESHRE/ASRM	Randomised, double blind	5	42	Metformin 500 mg tid+simvastatin 20 mg/day qd
Kazerooni	2010	Iran	12 weeks	ESHRE/ASRM	Randomised, double blind	5	42	Metformin 500 mg tid
Sathyapalan	2009	UK	6 months	ESHRE	Randomised, double blind	5	19	Atorvastatin 20 mg/day qd 3 months, metformin 500 mg tid 3 months
Sathyapalan	2009	UK	6 months	ESHRE	Randomised, double blind	5	18	Placebo 3 months, metformin 500 mg tid 3 months

*Sathyapalan, included three data sets that have been separately analysed.
ASRM, American Society for Reproductive Medicine; bid, two times a day; ESHRE, the Rotterdam European Society for Human Reproductive and Embryology; NIH, the 1990 National Institutes of Health; PCOS, polycystic ovary syndrome; qd, four times a day; tid, three times a day.